Skip to content

OncoDNA

Active Public limited companyfounded 2012active for 13 yearsRue Louis Breguet 1, 6041 CharleroiKBO/BCE: BE 0501.631.837

Annual accounts 2025

full format, filed on 14-07-2026, 17 days before the deadline
€2.1m
▲ 72.3%
-€2.1m
▲ €1.4m
-€3.8m
▲ €1.4m
€39,003
▲ €2.1m
-4.9%
▼ 11.5 percentage points
1.02
▲ 0.33

The turnover shown is an estimate from the gross margin.

Turnover ≈ €1.8m. Estimated: probably between €1.7m and €2.7m.

Balance sheet

balance sheet total €5.3m on 31-12-2025
What the company ownsHow it is paid for

in €m

in €m

Position in the sector

-4.9%

Lower than 95% of 784 companies in 2025.

1.02

Higher than 21% of 771 companies in 2025.

-72.0%

Lower than 95% of 776 companies in 2025.

OncoDNA Middle half of the sector 80% of the sector Full accounts in human health (NACE 86)

Net result: bottom quarter · Equity: bottom quarter · Balance sheet total: top quarter · Working capital: middle half · Staff: middle half

Staff

€114,892

Staff costs divided by the average number of full-time equivalents.

+1 person

people who joined people who left

In 2025, 4 people joined and 3 left. Training hours in 2025: 12.

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend2025202420232022202120202019201820172016201520142013
Balance sheet: assets
20/58 5.3m11.4m13.4m19.9m24.3m28.3m10.2m7.5m5.4m5.2m2.5m1.6m671,201
20 42,37362,78197,92373,614125,541201,887272,304255,432278,570240,341101,9268,94511,926
21/28 3.2m6.6m9.7m16.1m16.5m16.4m5.0m4.3m2.6m1.3m1.1m520,300340,299
21 2.3m3.8m5.1m6.2m6.6m6.6m4.8m3.4m2.1m1.1m933,878490,524314,391
22/27 6,19025,23851,15467,88037,01945,71953,90073,00796,06361,43228,05720,78113,932
23 61415,12029,62737,082-2,0406,51010,1889,4326,9719,9277,599-
24 5,5767,95816,99823,88127,62226,52318,82246,28972,71654,46218,13013,18213,932
25 --210210210--------
26 -2,1604,3196,7089,18711,75214,14116,52913,915----
28 846,3092.7m4.5m9.9m9.9m9.8m176,555819,548356,555153,895505050
29/58 2.1m4.8m3.6m3.7m7.7m11.7m4.9m2.9m2.6m3.6m1.5m1.1m330,902
3 143,861119,998198,317108,008---------
30/36 143,861119,998198,317108,008---------
40/41 1.4m1.8m1.4m1.4m1.9m2.1m2.3m2.0m1.7m1.4m771,934825,059250,117
40 1.1m1.7m1.2m1.2m1.3m1.2m1.3m886,068897,3581.1m339,090309,47861,925
41 282,09774,580118,191165,652540,933912,0561.0m1.1m772,283223,055432,844515,581188,192
50/53 -1.7m500,000----------
54/58 520,6091.1m1.5m2.1m5.7m9.5m2.5m869,022805,4412.2m693,154191,70780,785
490/1 39,49782,29449,818114,538149,881129,587111,44952,66390,46250,7502,88761,510-
Balance sheet: equity and liabilities
10/49 5.3m11.4m13.4m19.9m24.3m28.3m10.2m7.5m5.4m5.2m2.5m1.6m671,201
10/15 -256,642755,7415.8m10.0m16.6m15.9m4.5m30,677903,9372.3m572,5716,084343,524
10/11 4.3m14.8m14.8m30.5m30.5m24.4m8.2m1.2m7.0m5.1m1.1m320,000295,000
10 1.6m14.8m14.8m30.5m30.5m--------
100 1.6m14.8m14.8m30.5m30.5m30.0m10.2m1.2m8.9m8.8m1.1m640,000640,000
101 -----5.6m2.0m-1.9m3.8m-320,000345,000
11 2.7m------------
1100/10 2.7m------------
14 -5.6m-15.5m-10.4m-22.3m-16.2m-10.9m-5.5m-2.4m-6.8m-3.1m-1.1m-650,937-105,610
15 1.0m1.5m1.4m1.9m2.3m2.5m1.8m1.2m685,468262,662503,081337,021154,134
16 -107,25066,64132,00035,000180,00029,71863,05389,672----
160/5 -107,25066,64132,00035,000180,00029,71863,05389,672----
164/5 -107,25066,64132,00035,000180,00029,71863,05389,672----
17/49 5.5m10.5m7.5m9.9m7.7m12.2m5.6m7.4m4.4m3.0m2.0m1.6m327,678
17 3.4m3.4m2.5m3.3m3.9m7.5m2.9m4.0m2.7m1.1m850,928921,021-
170/4 3.4m3.4m2.5m3.3m3.9m7.5m2.9m4.0m2.7m1.1m850,928921,021-
42/48 2.0m6.9m4.8m6.6m3.8m4.7m2.6m3.4m1.6m1.7m1.1m453,363107,053
42 287,8384.1m1.7m3.1m803,555727,998342,351355,206426,081341,587221,416145,286-
43 -50,569697,979705,243-918,993205,6871.0m-7,561---
430/8 -50,569697,979705,243-918,993205,6871.0m-7,561---
44 1.3m1.9m1.6m1.9m2.0m2.2m1.4m1.3m683,2491.0m706,095247,45674,730
440/4 1.3m1.9m1.6m1.9m2.0m2.2m1.4m1.3m683,2491.0m706,095247,45674,730
46 --107,213118,585101,27433,68840,02933,92216,80832,63259,497--
45 345,653495,325519,820578,456698,319712,430564,754577,639454,202243,959112,42960,62132,323
450/3 3,7053,2984,43872,33365,38769,43749,12962,8184,50044,80816,3559,8753,118
454/9 341,948492,027515,383506,123632,932642,993515,625514,821449,702199,15196,07450,74629,204
47/48 107,966292,346266,204223,525134,58737,3324,56740,04529,84880,010---
492/3 81,640230,004111,04125,00039,00054,000151,69227,500144,590111,8618,950218,108220,625
Income statement
9900 2.1m1.2m769,457-439,603162,823-578,8761.7m973,82721,107-297,772307,375-75,82327,677
62 2.4m2.6m3.0m3.0m3.3m3.6m3.0m3.6m3.0m1.2m601,709354,023137,906
630 1.6m1.6m1.6m1.5m196,377482,611427,347477,909529,383471,564173,776157,23688,545
631/4 66,22244,879153,536550,558170,40935,059583,388101,03972,33743,804---
635/8 -107,25040,60934,641-3,000-145,000150,282-33,335-26,61989,672----
640/8 305,126490,0051.1m774,315774,218225,470106,869160,39276,5505,1101,4881,196381
66A 103-7,717150,378--642,993------
9901 -2.1m-3.5m-5.1m-6.4m-4.2m-5.1m-2.4m-3.3m-3.8m-2.0m-469,598-588,278-199,155
75/76B 530,852616,529557,402498,591981,85846,10944,26587,131100,02435,45687,84571,73595,813
75 530,852616,529529,713493,617652,83346,10944,26587,131100,02435,45687,84571,73595,813
76B --27,6894,974329,024--------
65/66B 2.2m2.2m5.8m230,5592.1m373,160730,30865,13252,08351,96537,13628,0342,268
65 305,924420,933360,676230,559256,364373,16087,31565,13252,08351,96537,13628,0342,268
66B 1.9m1.8m5.5m-1.8m-642,993------
9903 -3.8m-5.1m-10.4m-6.1m-5.3m-5.4m-3.1m-3.3m-3.7m-2.0m-418,889-544,577-105,610
67/77 3,70515,396613,330558,4004,9022,3364,909-684750-
9904 -3.8m-5.1m-10.4m-6.1m-5.3m-5.4m-3.1m-3.3m-3.7m-2.0m-419,573-545,327-105,610
9905 -3.8m-5.1m-10.4m-6.1m-5.3m-5.4m-3.1m-3.3m-3.7m-2.0m-419,573-545,327-105,610
Appropriation of the result
9906 -5.6m-15.5m-10.4m-22.3m-16.2m-10.9m-5.5m-10.1m-6.8m-3.1m-1.1m-650,937-105,610
14P -1.8m-10.4m--16.2m-10.9m--------
791/2 -------7.7m-----
Social balance sheet
9087 20.62230.731.533.837.531.238.1401810.46.22
Hours worked1013 35,15337,35951,50751,89457,32255,25451,26963,06268,89731,04618,03310,5343,044
Document PDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDF

The notes to these accounts have 25 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the accounts filed with the NBB.

Source: Annual accounts 2025 at the NBB, filed on 14-07-2026.

Download as CSV

Filings

each dot is a set of accounts, on the day it reached the National Bank
Financial year Type Filed Reference Document
31-12-2025 full format 14-07-2026 2026-00296980 PDF
31-12-2024 full format 30-07-2025 2025-00331910 PDF
31-12-2023 full format 23-07-2024 2024-00278507 PDF
31-12-2022 full format 05-07-2023 2023-00211592 PDF
31-12-2021 full format 22-06-2022 2022-20081999 PDF
31-12-2020 full format 21-06-2021 2021-21900404 PDF
31-12-2019 full format 02-07-2020 2020-25600430 PDF
31-12-2018 full format 05-07-2019 2019-29200295 PDF
31-12-2017 full format 21-06-2018 2018-21300413 PDF
31-12-2016 full format 06-06-2017 2017-15600208 PDF
31-12-2015 full format 11-07-2016 2016-29800432 PDF
31-12-2014 full format 23-06-2015 2015-19600579 PDF
31-12-2013 full format 27-06-2014 2014-22000211 PDF

Subsidies and aid

European Union 2023, 1 entry, €121,194 in total

European Regional Development Fund (ERDF)
€121,194

Projects

  • DIGIONE I3 - DIGITAL INFRASTRUCTURE FOR ONCOLOGY IN EUROPEEuropean Regional Development Fund, 01-11-2023 to 30-04-2026, €121,194

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend2025202420232022202120202019201820172016201520142013
-551,078-1.9m-3.5m-4.9m-4.0m-4.6m-2.0m-2.8m-3.3m-1.5m-295,822-431,042-110,610
-2.2m-3.5m-8.7m-4.7m-5.1m-4.9m-2.7m-2.8m-3.2m-1.5m-245,797-388,091-17,065
37,682253,161593,9291.3m2.8m11.7m1.6m2.1m1.7m788,227621,424337,236413,937
-541,467-436,352-617,455-3.6m-3.8m7.0m1.6m63,582-1.4m1.5m501,447110,922-
39,003-2.1m-1.2m-2.9m3.9m7.0m2.3m-450,446955,3561.9m368,538624,913223,850
-4.9%6.6%43.6%50.2%68.2%56.2%44.4%0.4%16.7%43.3%22.6%0.4%51.2%
1.020.690.740.562.042.501.900.871.592.111.342.383.09
0.950.680.700.542.042.501.900.871.592.111.342.383.09
-13.931.280.990.460.771.24-4.891.313.42-0.95
--680.7%-177.6%-61.4%-31.7%-34.0%-69.4%--414.0%-88.5%-73.3%--30.7%
-72.0%-45.2%-77.5%-30.8%-21.6%-19.1%-30.8%-43.7%-69.2%-38.3%-16.6%-34.1%-15.7%
-1.80-4.58-9.68-21.46-15.55--------

EBIT margin: not included in this filing.

Debt to equity is not shown because equity is negative. Debt divided by negative equity means nothing.

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Social balance sheet

Item31-12-202531-12-202431-12-202331-12-202231-12-2021
Employees at the balance-sheet date-20303234
full-time-17273032
part-time-3322
in full-time equivalents20.419.529.531.733.6
20.62230.731.533.8
On a permanent contract2120303232
Joined41376
Left311597
Training hours121101,38216,796-

Source: social balance sheet in the 2021 to 2025 annual accounts

Securities and guarantees

on own assets and for others
Item20252024202320222021
Debts secured on the company's own assets€1.4m€1.4m€1.4m€1.4m€1.4m
Debts guaranteed by Belgian public bodies€300,000€1.1m€1.1m€1.1m€1.1m
€2.1m€2.1m€2.1m€2.1m€2.1m

Source: notes to the 2021 to 2025 annual accounts (statement of debts and off-balance-sheet rights and commitments)

Investments

fixed assets acquired
Item20252024202320222021
Tangible fixed assets€3,798€1,637€6,135€53,564€19,158
Intangible fixed assets€33,884€251,525€527,524€1.3m€2.6m
Financial fixed assets--€60,270-€137,400
€1.6m€1.6m€1.6m€1.5m€196,377

Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)

Public contracts

1 award · 2023
Achats pré-commerciaux pour l'acquisition de services de R&D pour le développement d'une solution pour l'analyse des biopsies liquides de tumeurs solides basée sur la technologie NGS. tumeurs solides, basée sur la technologie NGS
buyer: SciensanoResearch and development servicesawarded 20-01-2023€642,4007 tendersTED 75218-2023

Source: TED (Tenders Electronic Daily), Publications Office of the European Union. The values are as the buyer published them. For a framework agreement, the value is a ceiling.

Insights on OncoDNA

The operating result for 2025 is a loss of €2.1m, smaller than the loss of €3.5m in 2024.

Equity is negative. Debt (€5.5m) exceeds the balance-sheet total (€5.3m).

Large changes and their cause
  • 2025 Total assets -54% on 2024. Capital reduction of €13,683,878 (Official Gazette 18-04-2025). Capital reduction of €13,683,878 (Official Gazette 18-04-2025).

Next steps